This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Alpine Immune Sciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.
Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Alpine Immune Sciences (ALPN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy
5 Best Stocks to Buy Ahead of Q1 Earnings Season
by Tirthankar Chakraborty
Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016. Revenues are expected to rise 4.6%.
Will Nivalis Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
Top Ranked Momentum Stocks to Buy for March 15th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 15th:
Analysts Estimate Alpine Immune Sciences (ALPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
by Zacks Equity Research
FibroGen (FGEN) was a big mover last session, as the company saw its shares rise over 48% on the day amid huge volumes.
Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
by Zacks Equity Research
Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.
New Strong Buy Stocks for August 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday